CLEVELAND, Nov. 28, 2012 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DATA), a leader in developing cloud-based, unified eClinical technologies and delivering related services for the clinical trials industry, today announced Comprehensive Clinical Development (Comprehensive) has signed a multi-year, Enterprise Agreement to standardize on the D ATATRAK ONE™ cloud-based clinical research platform, for all clinical trials. The agreement extends to the complete D ATATRAK ONE™ unified software suite, including uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR.
A clinical research company with specific expertise in managing early phase clinical trials, Comprehensive completed D ATATRAK's Accreditation Training Program and quickly began designing and implementing its studies using the D ATATRAK ONE™ uDesign product. The D ATATRAK Enterprise Agreement licenses all D ATATRAK products, allowing Comprehensive the flexibility to custom deliver the right technology modules from the D ATATRAK ONE™ suite for each trial.
"Using a single platform for our clinical data management systems provides valuable flexibility," said Julian Rimmer, VP & General Manager, Clinical Services at Comprehensive. "Additionally, faster access to data will facilitate quicker decisions and greater benefits for our clients."
"It's great to see another client leverage the benefits of our unified clinical enterprise solution," stated Dr. Bill Gluck, D ATATRAK's Vice President of Clinical and Consulting Services. "With this agreement, Comprehensive will be able to package their expertise around our truly cloud-based clinical research platform and build a competitive advantage in early phase delivery as they tailor the full suite of D ATATRAK ONE™ products to their customers' unique study needs and specifications."About Comprehensive Clinical Development Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical services in a broad range of therapeutic areas. Comprehensive maintains an outstanding record for consistently delivering quality and success on time and within budget. As a leader in the field of Phase I clinical pharmacology, Comprehensive holds a solid track record of collecting early safety and efficacy data across both healthy and specialty populations and offers distinct capabilities in clinical research. For more information, please see http://www.comprehensivecd.com. D ATATRAK ONE™ The D ATATRAK ONE™ Clinical Research Platform is an easy to use, cloud-based clinical enterprise solution that empowers Sponsors and CROs to efficiently design, deliver and manage clinical trials. From strategy and planning to resource management and study execution needs, clients manage their entire product portfolio in a single system with one username and password. D ATATRAK's unified clinical enterprise solution consists of seven products: uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR. About D ATATRAK D ATATRAK is the leader of unified eClinical™ technologies and related services for the clinical trials industry. Using the D ATATRAK ONE™ multi-product, cloud-based clinical research platform, D ATATRAK 's Clinical and Consulting Services™ group assists clients in conducting Phase I-IV drug and device studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit www.datatrak.net. Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 14, 2012 announcing its results for the three-month period ending September 30, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.